Mon panier

Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
RSV-MY2232-100ug
$425.00
RSV-MY2232-1mg (500ug X 2)
$2790.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.

  • Clone

    8G9

  • Species

    Mouse

  • Isotype

    Human IgG1 | Human Kappa

  • Conjugate

    Unconjugated

  • Antibody Type

    Recombinant Monoclonal

  • Reactivity

    Virus

  • Immunogen

    Recombinant HRSV (A) Glycoprotein G Protein is expressed from human 293 cells

  • Specificity

    Specific recognition of HRSV (A) Glycoprotein G Protein.

  • Application

    Application
    Recommended Usage
    ELISA
    0.1-125 ng/mL
  • Purity

    95% as determined by SDS-PAGE.

    90% as determined by SEC-MALS.

  • Purification

    Protein A purified / Protein G purified

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

    For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Cross Verification

    This product No cross-reactivity in ELISA with

    HRSV (B) Glycoprotein G Protein, His Tag (Cat. No. GLG-V5144).

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    HRSV Glycoprotein (RSV-G) SDS-PAGE

    Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    HRSV Glycoprotein (RSV-G) SEC-MALS

    The purity of Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) (Cat. No. RSV-MY2232) is more than 90% and the molecular weight of this protein is around 135-165 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HRSV Glycoprotein (RSV-G) ELISA

    Immobilized HRSV (A) Glycoprotein G Protein, His Tag (Cat. No. RSG-V5221) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) (Cat. No. RSV-MY2232) with a linear range of 0.1-4 ng/mL (QC tested).

    Protocol
  •  HRSV Glycoprotein (RSV-G) ELISA

    Immobilized HRSV (A) Glycoprotein G Protein, His Tag (Cat. No. GLG-V5143) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-HRSV Glycoprotein (RSV-G) Antibody, Human IgG1 (8G9) (Cat. No. RSV-MY2232) with a linear range of 0.1-4 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

The two major glycoproteins on the surface of the RSV virion, the attachment glycoprotein (G) and the fusion (F) glycoprotein, control the initial phases of infection. The central region of the G protein contains a 13-amino acid highly conserved domain, partially overlapping the cysteine noose domain with 4 cysteines linked 1–4 and 2–3, followed by a highly basic heparin-binding domain (HBD). The HBD is the likely attachment site for heparan sulfate (HS) found on the surface of most cells. A peptide from the G protein HBD (amino acids 184–198) binds efficiently to HEp-2 cells and inhibits RSV infection.

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte